Rønjom Marianne F, Brink Carsten, Lorenzen Ebbe L, Hegedüs Laszlo, Johansen Jørgen
a Department of Oncology , Odense University Hospital , Odense , Denmark.
Acta Oncol. 2015;54(8):1188-94. doi: 10.3109/0284186X.2014.1001034. Epub 2015 Jan 28.
To examine the variations of risk-estimates of radiation-induced hypothyroidism (HT) from our previously developed normal tissue complication probability (NTCP) model in patients with head and neck squamous cell carcinoma (HNSCC) in relation to variability of delineation of the thyroid gland.
In a previous study for development of an NTCP model for HT, the thyroid gland was delineated in 246 treatment plans of patients with HNSCC. Fifty of these plans were randomly chosen for re-delineation for a study of the intra- and inter-observer variability of thyroid volume, Dmean and estimated risk of HT. Bland-Altman plots were used for assessment of the systematic (mean) and random [standard deviation (SD)] variability of the three parameters, and a method for displaying the spatial variation in delineation differences was developed.
Intra-observer variability resulted in a mean difference in thyroid volume and Dmean of 0.4 cm(3) (SD ± 1.6) and -0.5 Gy (SD ± 1.0), respectively, and 0.3 cm(3) (SD ± 1.8) and 0.0 Gy (SD ± 1.3) for inter-observer variability. The corresponding mean differences of NTCP values for radiation-induced HT due to intra- and inter-observer variations were insignificantly small, -0.4% (SD ± 6.0) and -0.7% (SD ± 4.8), respectively, but as the SDs show, for some patients the difference in estimated NTCP was large.
For the entire study population, the variation in predicted risk of radiation-induced HT in head and neck cancer was small and our NTCP model was robust against observer variations in delineation of the thyroid gland. However, for the individual patient, there may be large differences in estimated risk which calls for precise delineation of the thyroid gland to obtain correct dose and NTCP estimates for optimized treatment planning in the individual patient.
为研究头颈部鳞状细胞癌(HNSCC)患者中,我们之前开发的正常组织并发症概率(NTCP)模型对辐射诱发甲状腺功能减退症(HT)风险估计的变化情况,该变化与甲状腺勾画的变异性有关。
在之前一项开发HT的NTCP模型的研究中,对246名头颈部鳞状细胞癌患者的治疗计划进行了甲状腺勾画。随机选择其中50个计划进行重新勾画,以研究甲状腺体积、平均剂量(Dmean)及HT估计风险的观察者内和观察者间变异性。采用Bland-Altman图评估这三个参数的系统(均值)和随机[标准差(SD)]变异性,并开发了一种显示勾画差异空间变化的方法。
观察者内变异性导致甲状腺体积和平均剂量的平均差异分别为0.4 cm³(标准差±1.6)和 -0.5 Gy(标准差±1.0),观察者间变异性导致的差异分别为0.3 cm³(标准差±1.8)和0.0 Gy(标准差±1.3)。由于观察者内和观察者间变异导致的辐射诱发HT的NTCP值相应平均差异极小,分别为 -0.4%(标准差±6.0)和 -0.7%(标准差±4.8),但如标准差所示,对于部分患者,估计的NTCP差异很大。
对于整个研究人群,头颈部癌中辐射诱发HT的预测风险变化较小,我们的NTCP模型对观察者甲状腺勾画的变异具有稳健性。然而,对于个体患者,估计风险可能存在较大差异,这就需要精确勾画甲状腺,以获得正确的剂量和NTCP估计值,用于个体患者的优化治疗计划。